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Abstract 
In this article the short description of soft contact lenses materials in terms of their use in the ophthalmic therapeutic 
systems and experimental results of their adsorptive properties in combination with the ophthalmic solution of 
Betaxolol hydrochloride are presented. Preliminarily it is determined that Russian pharmaceutical market of anti-
glaucoma drug products and soft contact lenses can be characterized as a widely various. It is also known that currently 
the research of the alternative drug delivering systems is a relevant scientific field. In this research the soft contact 
lenses of brand 1-DAY ACUVUE® MOIST (Etafilcon A) and 0.5% ophthalmic solution of Betaxolol hydrochloride 
were chosen. The assay of betacolol hydrochloride in its ophthalmic solution before and after the process of adsorption 
was carried out by UV-spectrophotometry method. The evaluation of contact lenses adsorption potential was performed 
as a difference in concentrations between the native solution and the solution obtained after the adsorption. It’s defined 
that within 10 hours the soft contact lenses adsorb 7.23 mg of Betaxolol hydrochloride from 3 ml of solution, which is 
sufficient for therapeutic effect. Preliminarily it’s possible to conclude that that soft contact lenses 1-DAY ACUVUE® 
MOIST can be recommended for use in the ophthalmic therapeutic system in combination with the ophthalmic solution 
of Betaxolol hydrochloride. 
 
Introduction 
 
According to the data of World Health 
Organization, one of the most hazardous eye disease is 
glaucoma. Glaucoma is defined as a whole group of 
ophthalmic disorders, which is characterized by the 
constant or episodic increasing of the intraocular 
pressure (IOP) much higher than appropriate for people 
normal daily activity. If glaucoma is not cured on time, 
then it leads directly to irreversible destruction of retina 
[1]. Nowadays the relationship is investigated between 
pathogenesis of glaucoma and pathogenesis of the 
other eye disorders, especially those once that include 
the refractive system errors, in particular, myopia. With 
the probability of 85% glaucoma develops in the eyes 
that already have the myopic background. So, the 
patients with the eye refraction system errors are in the 
high-risk group of IOP increase and hence, glaucoma 
development [2].  
Both for glaucoma treatment and the majority of 
other ophthalmic diseases it is justified to use the drug 
products that perform a local effect, in the majority of 
cases they are the eye drops. But it is known that only 
5% of the active ingredient from one therapeutic dose 
is able to provide the therapeutic effect, but the other 
part goes to the system blood blood flow spreading all 
over the organism and causing the big number of 
negative side effects development. Moreover, it’s 
determined that contact time of the ophthalmic solution 
with eye surface is rare to be more than 2 minutes 
while it’s instilled [3]. 
In order to mitigate the disadvantages of the eye 
drops and to prevent the negative consequences of their 
use, the research and development of the new ways of 
extended and more safe ophthalmic eye delivery were 
launched, for instance, trying to increase the viscosity 
of the eye drops and various content recombination of 
the ophthalmic solutions, so the eye drops would pass 
through the cornea in more significant amounts [4, 6]. 
One of the most prospective and the relatively newest 
way vectors in the field of the controlled drug delivery 
is the development of the specialized ophthalmic 
therapeutic systems (OTS). In OTS the soft contact 
lenses (SCL) of various polymeric materials are 
supposed to be used as the drug carriers with the 
prolonged release [7, 8].  
In the framework of the seeking of the new methods 
of drug therapy the development of this vector is 
justified by the high rate of glaucoma occurring in the 
background of myopia and by the tendency to the 
popularization of contact correction of the refractive 
system errors, which is getting more relevant these 
days among various groups of population.  
That is why the aim of this research is the 
experimental study of etafilcon A soft contact lenses as 
a potential drug carrier using the 0.5% ophthalmic 
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solution of Betaxolol hydrochloride within the 
ophthalmic therapeutic system for treatment of 
glaucoma combined with myopia. 
 
Materials and Methods of Research 
 
In this research the soft contact lenses of brand 1-
DAY ACUVUE® MOIST of etafilcon A and 0.5% 
ophthalmic solution of Betaxolol hydrochloride were 
used. 
Method of assay for 0.5% ophthalmic solution of 
Betaxolol hydrochloride [10, 11, 12]. 
As the first step of this study, it was necessary to 
define the quantity of Betaxolol hydrochloride in its 
solution before the adsorption process is performed. 
The assay was carried out in Belgorod State National 
Research University, department of Pharmaceutical 
technology, using the method of UV-
spectrophotometry with the help of the 
spectrophotometer SF-104. All calculations were done 
using the relative absorption coefficient for Betaxolol 
hydrochloride according to the formula 1: 
С𝑥 =
𝑊 × 𝐷
𝐸1см
1% × 𝑙
      ,   (1) 
where W – determined dissolution rate for the assay 
of Betaxolol hydrochloride solution, which equals 50; 
𝐸1см
1%  – specific relative absorption coefficient of 
Betaxolol hydrochloride, which value is 38 in purified 
water [9]; 
D – optical density; 
l – length of the spectrophotometric cells, which 
equals 10 mm. 
The assay was carried out in the condition of the 
highest precision, which is why the in accordance with 
confidence level P = 99%, the value of Student’s t-
criterion t(P,f) was chosen as 3.71.  
 Method of soft contact lenses saturation with the 
soluton of Betaxolol hydrochloride.  
To evaluate the adsorptive potential of the studied 
soft contact lenses, their tentative saturation was 
performed in the defined way: into 6 containers for soft 
contact lenses with 3 ml of 0.5% Betaxolol 
hydrochloride solution, 1 contact lens was put each. 
Every 2 hours from each container 1 contact lens was 
ejected, the concentration of the obtained solution was 
measured. The total time of the experiment was 10 
hours. 
 Evaluation of the adsorption potential of soft 
contact lenses containing Betaxolol hydrochloride. 
 The preparation of the sample remained the 
same for the obtained solution after the sorption 
process as for assay of the native 0.5% ophthalmic 
solution of Betaxolol hydrochloride.  
 To evaluate the amount of the adsorbed 
Betaxolol hydrochloride the volume of the container 
must be taken into account and calculated using the 
formula 2: 
msrp = (C0 − Ci) × 3  ,       (2) 
where msrp – amount of Betaxolol hydrochloride in 
soft contact lenses, mg; 
C0 – initial concentration of the Betaxolol 
hydrochloride solution before the sorption process, 
mg/ml; 
Cx – concentration of the Betaxolol hydrochloride 
solution after i-hours of sorption, mg/ml; 
3 – volume of the container filled, ml. 
 
Results and Discussion 
 
The results of the six-fold assay for 0.5% Betaxolol 
hydrochloride ophthalmic solution and their statistical 
processing is presented in table 1.
 
Таблица 1 – The results of assay for Betaxolol hydrochloride in the ophthalmic solution and evaluation of the test 
method correctness 
n 𝐶𝑖 С 𝑆 𝜀С Δ% 
1 0.563 
0.551 8.23×10-3 0.015 2.69 
2 0.552 
3 0.551 
4 0.538 
5 0.554 
6 0.547 
 
From table 1 it’s seen that the method of the assay 
for Betaxolol hydrochloride in ophthalmic solution is 
correct and precise. The relative error of the method 
equals 2.69%. 
The next step was the saturation of the studied soft 
contact lenses in the way described above in this 
article. 
The dynamics of the adsorption of Betaxolol 
hydrochloride by soft contact lenses from the solution 
is shown in picture 1 and table 2. 
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Picture 1 – Dynamics of etafilcon A soft contact lenses saturation by Betaxolol hydrochloride ophthalmic solution 
within the defined time 
 
As it’s seen from the picture 1, the adsorption 
process appeared to be more intensive within 6 hours, 
after that the adsorption speed of Betaxolol 
hydrochloride became slower.
 
Таблица 2 – Results of evaluation for Betaxolol hydrochloride content in soft contact lenses of etafilcon A  
 
Adsorption process time, h 
0 2 4 6 8 10 
Di of obtained solution 0.428 0.344 0.303 0.253 0.242 0.239 
Ci of obtained solution, mg/ml 5.63 4.53 3.98 3.33 3.18 3.15 
Betaxolol h/cl in lenses (msrp), 
mg 
0 3.30 4.75 6.90 7.16 7.23 
 
According to the data from table 2, 7.23 mg of 
Betaxolol hydrochloride are adsorbed by etafilcon A 
soft contact lenses from 3 ml solution within 10 hours 
of the experiment. The daily exposure of Betaxolol 
hydrochloride was calculated and appeared to be 1.12 
mg if it’s used twice a day 2 drops into each eye as it’s 
recommended in the instruction for the drug product. 
Hence, the therapeutic concentration of Betaxolol 
hydrochloride in soft contact lenses is reached after 2 
hours of their saturation.  
 
Conclusion 
 
In the framework of the performed complex of 
experiments the UV-spectrophotometric method of 
assay for 0.5% ophthalmic solution of Betaxolol 
hydrochloride was optimized and further justified and 
carried out for assay of Betaxolol hydrochloride in the 
solution after 10 hours of soft contact lenses saturation. 
Statistically it was determined that the assay method of 
Betaxolol hydrochloride meets the acceptance criteria 
requirements for precision and repetitiveness if 99% of 
confidence level is taken into account. The relative 
error appeared to be 2.69%, which is appropriate value 
that allows the method to be used in further research 
using various materials of soft contact lenses.  
During the evaluation of adsorptive potential of 
etafilcon A soft contact lenses it was determined, that 
the therapeutic concentration of Betaxolol 
hydrochloride in them is reached within 2 hoursand 
equals 3.30 mg. Overall amount of Betaxolol 
hydrochloride taken from the solution within 10 hours 
of the experiment equals 7.23 mg. Hence, etafilcon A 
soft contact lenses of brand 1-DAY ACUVUE® 
MOIST are preliminarily recommended for use in 
therapeutic ophthalmic system as a drug carrier of 
Betaxolol hydrochloride for treatment of glaucoma 
combined with myopia. 
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